As shown in Table 1, the expression levels of SLC6A1 mRNA in prostate cancer patients with high Gleason score (P < 0.001), advanced clinical stage (P < 0.001) and positive PSA failure (P = 0.042) were significantly higher than those with low Gleason score, early clinical stage and negative PSA failure. The gene discussed is SLC6A1; the disease is prostate carcinoma.